Targeted drug delivery to tumors: Myths, reality and possibility

Hoffman, 2008, The origins and evolution of “controlled” drug delivery systems, J. Control. Release, 132, 153, 10.1016/j.jconrel.2008.08.012

Florence, 2007, Pharmaceutical nanotechnology: more than size. Ten topics for research, Int. J. Pharm., 339, 1, 10.1016/j.ijpharm.2007.06.009

Ruenraroengsak, 2010, Nanosystem drug targeting: facing up to complex realities, J. Control. Release, 141, 265, 10.1016/j.jconrel.2009.10.032

Damia, 2009, Contemporary pre-clinical development of anticancer agents — what are the optimal preclinical models?, Eur. J. Cancer, 45, 2768, 10.1016/j.ejca.2009.08.008

Suggitt, 2005, 50years of preclinical anticancer drug screening: empirical to target-driven approaches, Clin. Cancer Res., 11, 971, 10.1158/1078-0432.971.11.3

Gao, 2011, Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles, J. Control. Release, 152, 84, 10.1016/j.jconrel.2011.01.021

Jain, 2010, Delivering nanomedicine to solid tumors, Nat. Rev. Clin. Oncol., 7, 653, 10.1038/nrclinonc.2010.139

Visvader, 2011, Cells of origin in cancer, Nature, 469, 314, 10.1038/nature09781

Torchilin, 2000, Drug targeting, Eur. J. Pharm. Sci., 11, S81, 10.1016/S0928-0987(00)00166-4

Gerber, 2008, Targeted therapies: a new generation of cancer treatments, Am. Fam. Physician, 77, 311

Mimeault, 2008, Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies, Clin. Pharmacol. Ther., 83, 673, 10.1038/sj.clpt.6100296

Strebhardt, 2008, Paul Ehrlich's magic bullet concept: 100years of progress, Nat. Rev. Cancer, 8, 473, 10.1038/nrc2394

Mills, 1999, Targeted drug delivery, Expert Opin. Ther. Patents, 9, 1499, 10.1517/13543776.9.11.1499

Beduneau, 2007, Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments, Biomaterials, 28, 4978, 10.1016/j.biomaterials.2007.05.014

Deckert, 2009, Current constructs and targets in clinical development for antibody-based cancer therapy, Current Drug Targets, 10, 158, 10.2174/138945009787354502

Hong, 2009, Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin, J. Control. Release, 133, 96, 10.1016/j.jconrel.2008.09.005

Zensi, 2009, Albumin nanoparticles targeted with ApoE enter the CNS by transcytosis and are delivered to neurons, J. Control. Release, 137, 78, 10.1016/j.jconrel.2009.03.002

Canal, 2010, Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates, J. Control. Release, 146, 388, 10.1016/j.jconrel.2010.05.027

Pirollo, 2008, Does a targeting ligand influence nanoparticle tumor localization or uptake?, Trends Biotechnol., 26, 552, 10.1016/j.tibtech.2008.06.007

Kirpotin, 2006, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models, Cancer Res., 66, 6732, 10.1158/0008-5472.CAN-05-4199

Mikhail, 2009, Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels, J. Control. Release, 138, 214, 10.1016/j.jconrel.2009.04.010

Rapoport, 2004, Combined cancer therapy by micellar-encapsulated drug and ultrasound, Int. J. Pharm., 277, 155, 10.1016/j.ijpharm.2003.09.048

Lentacker, 2008, New strategies for nucleic acid delivery to conquer cellular and nuclear membranes, J. Control. Release, 132, 279, 10.1016/j.jconrel.2008.06.023

Lin, 2010, Quantitative and qualitative investigation into the impact of focused ultrasound with microbubbles on the triggered release of nanoparticles from vasculature in mouse tumors, J. Control. Release, 146, 291, 10.1016/j.jconrel.2010.05.033

Nam, 2009, Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles, J. Control. Release, 135, 259, 10.1016/j.jconrel.2009.01.018

Sauer, 2009, Dynamics of magnetic lipoplexes studied by single particle tracking in living cells, J. Control. Release, 137, 136, 10.1016/j.jconrel.2009.04.003

Raagel, 2009, CPP-protein constructs induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway, J. Control. Release, 139, 108, 10.1016/j.jconrel.2009.06.028

Richardson, 2009, Intracellular fate of bioresponsive poly(amidoamine)s in vitro and in vivo, J. Control. Release, 142, 78, 10.1016/j.jconrel.2009.09.025

Sasaki, 2010, Monitoring intracellular degradation of exogenous DNA using diffusion properties, J. Control. Release, 143, 104, 10.1016/j.jconrel.2009.12.013

Maeda, 1985, Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein-neocarzinostatin: pronounced improvements in pharmacological properties, J. Med. Chem., 28, 455, 10.1021/jm00382a012

Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS, Cancer Res., 46, 6387

Konno, 1983, Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report, Eur. J. Cancer Clin. Oncol., 19, 1053, 10.1016/0277-5379(83)90028-7

Valerio-Lepiniec, 2002, Key interactions in neocarzinostatin, a protein of the immunoglobulin fold family, Protein Eng., 15, 861, 10.1093/protein/15.11.861

Courtice, 1963, The origin of lipoprotein in lymph, 89

Yuan, 1994, Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft, Cancer Res., 54, 3352

Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283

Barbé, 2004, Silica particles: a novel drug-delivery system, Adv. Mater., 16, 1, 10.1002/adma.200400771

Guan, 2007, Polymeric nanoparticles and nanopore membranes for controlled drug and gene delivery, 115

Savic, 2006, Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach, Langmuir, 22, 3570, 10.1021/la0531998

Savic, 2006, Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle–cell interactions, J. Drug Target., 14, 343, 10.1080/10611860600874538

Burt, 1999, Development of copolymers of poly(d, l-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel, Colloids Surf. B Biointerfaces, 16, 161, 10.1016/S0927-7765(99)00067-3

Chen, 2008, Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Förster resonance energy transfer imaging, Langmuir, 24, 5213, 10.1021/la703570m

Chen, 2008, Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Förster resonance energy transfer imaging, Proc. Natl. Acad. Sci. USA, 18, 6596, 10.1073/pnas.0707046105

Rippe, 2002, Transendothelial transport: the vesicle controversy, J. Vasc. Res., 39, 375, 10.1159/000064521

Lee, 2007, Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization, Biomacromolecules, 8, 202, 10.1021/bm060307b

Soppimath, 2007, Nanostructures for cancer diagnostics and therapy, 409

Ballet, 1990, Hepatic circulation: potential for therapeutic intervention, Pharmacol. Ther., 47, 281, 10.1016/0163-7258(90)90091-F

Lia, 2001, PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats, J. Control. Release, 71, 203, 10.1016/S0168-3659(01)00218-8

Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm., 307, 93, 10.1016/j.ijpharm.2005.10.010

Hobbs, 1998, Regulation of transport pathways in tumor vessles: role of tumor type and microenvironment, Proc. Natl. Acad. Sci. USA, 95, 4607, 10.1073/pnas.95.8.4607

Yuan, 1995, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res., 55, 3752

Choi, 2009, Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution, J. Mater. Chem., 19, 4102, 10.1039/b900456d

Yu, 2007, Nanotechnology and drug delivery, 93

Jania, 1992, Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose, Int. J. Pharm., 86, 239, 10.1016/0378-5173(92)90202-D

Bastian, 1998, Chemo-embolization of experimental liver metastases. Part 1. Distribution of biodegradable microspheres of different sizes in an animal model for the locoregional therapy, Eur. J. Pharm. Biopharm., 46, 243, 10.1016/S0939-6411(98)00047-2

Harris, 2001, Pegylation — a novel process for modifying pharmacokinetics, Clin. Pharmacokinet., 40, 539, 10.2165/00003088-200140070-00005

Yamaoka, 1994, Distribution and tissue uptake of poly(ethylene glycol) with different molecular-weights after intravenous administration to mice, J. Pharm. Sci., 83, 601, 10.1002/jps.2600830432

Yamaoka, 1995, Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration, J. Pharm. Pharmacol., 47, 479, 10.1111/j.2042-7158.1995.tb05835.x

Park, 2010, To PEGylate or not to PEGylate, that is not the question, J. Control. Release, 142, 147, 10.1016/j.jconrel.2010.01.025

Litzinger, 1994, Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes, Biochim. Biophys. Acta-Biomembranes, 1190, 99, 10.1016/0005-2736(94)90038-8

Capone, 1984, Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors, J. Natl. Cancer Inst., 72, 673

Wen, 1995, In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line, Neurosurgery, 36, 1158, 10.1227/00006123-199506000-00015

Li, 2010, Targeted toxins in brain tumor therapy, Toxins, 2, 2645, 10.3390/toxins2112645

Leamon, 2003, Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo, Bioconjugate Chem., 14, 738, 10.1021/bc020089t

Bae, 2009, Drug targeting and tumor heterogeneity, J. Control. Release, 133, 2, 10.1016/j.jconrel.2008.09.074

Roth, 2004, Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia, Nat. Rev. Drug Discov., 3, 353, 10.1038/nrd1346

Yuan, 1994, Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows, Cancer Res., 54, 4564

Jain, 1998, Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor, Proc. Natl. Acad. Sci. USA, 95, 10820, 10.1073/pnas.95.18.10820

Harrington, 2001, Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes, Clin. Cancer Res., 7, 243

Milosevic, 2004, The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure, Semin. Radiat. Oncol., 14, 249, 10.1016/j.semradonc.2004.04.006

Guyton, 1996, pp. 192

Lee, 2010, The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles, Mol. Pharm., 7, 1195, 10.1021/mp100038h

Louis, 2007, The 2007 WHO Classification of tumours of the central nervous system, Acta Neuropathol., 114, 97, 10.1007/s00401-007-0243-4

Levan, 1953, Endomitotic reduplication mechanisms in ascites tumors of the mouse, J. Natl. Cancer Inst., 14, 1

Dexter, 1982, Intraneoplastic diversity, Biochim. Biophys. Acta, 695, 97

Fidler, 1982, Biological diversity in metastatic neoplasms: origins and implications, Science, 277, 998, 10.1126/science.7112116

Heppner, 1983, Tumor heterogeneity: biological implications and therapeutic consequences, Cancer Metastasis Rev., 2, 5, 10.1007/BF00046903

Miller, 1982, Intratumor heterogeneity, Cancer Metastasis Rev., 1, 319, 10.1007/BF00124215

Poste, 1982, On the genesis and regulation of cellular heterogeneity in malignant tumors, Invasion Metastasis, 2, 137

Welch, 1985, The implication of tumor progression on clinical oncology, Clin. Exp. Matast., 3, 151, 10.1007/BF01786761

Adams, 2008, Is tumor growth sustained by rare cancer stem cells or dominant clones?, Can. Res., 68, 4018, 10.1158/0008-5472.CAN-07-6334

Shackleton, 2009, Heterogeneity in cancer: cancer stem cells versus clonal evolution, Cell, 138, 822, 10.1016/j.cell.2009.08.017

Charafe-Jauffret, 2009, Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature, Cancer Res., 69, 1302, 10.1158/0008-5472.CAN-08-2741

Hwang-Verslues, 2009, Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers, PLoS One, 4, e8377, 10.1371/journal.pone.0008377

Mani, 2008, The epithelial–mesenchymal transition generates cells with properties of stem cells, Cell, 133, 704, 10.1016/j.cell.2008.03.027

Gupta, 2009, Identification of selective inhibitors of cancer stem cells by high-throughput screening, Cell, 138, 645, 10.1016/j.cell.2009.06.034

Iliopoulos, 2011, Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion, Proc. Natl. Acad. Sci. USA, 108, 1397, 10.1073/pnas.1018898108

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Vincent, 2009, Polymer therapeutics: clinical applications and challenges for development Adv, Drug Deliver. Rev., 61, 1117, 10.1016/j.addr.2009.08.001

Welch, 1987, Biologic considerations for drug targeting in cancer patients, Cancer Treatment Rev., 14, 351, 10.1016/0305-7372(87)90029-6

Birner, 2001, Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer, Clin. Cancer Res., 7, 1669